Sight Sciences, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; the supplied filing text does not provide standalone fourth-quarter results. Amounts below are in U.S. dollars unless noted.
Business context
Sight Sciences develops and sells ophthalmic medical devices for glaucoma and dry eye disease. Its Surgical Glaucoma segment sells the OMNI Surgical System and, following its initial commercial launch in Q3 2022, the SION Surgical Instrument. Its Dry Eye segment sells the TearCare System. The company relies on third-party manufacturers and primarily sells in the United States.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $71.3 million | $49.0 million | +45.7% |
| Surgical Glaucoma revenue | $65.6 million | $46.5 million | +41.1% |
| Dry Eye revenue | $5.7 million | $2.5 million | +133.2% |
| Gross profit / gross margin | $59.0 million / 82.7% | $40.3 million / 82.4% | Margin +0.3 percentage points |
| Operating expenses | $142.9 million | $91.8 million | +55.6% |
| Operating loss | $84.0 million | $51.5 million | Loss widened |
| Net loss | $86.2 million | $63.0 million | Loss widened 37.0% |
| Net loss per share, diluted | $1.80 | $2.36 | Loss per share narrowed |
| Cash used in operating activities | $76.0 million | $52.5 million | Use increased |
OMNI accounted for 89% of FY2022 revenue; the Surgical Glaucoma segment represented 92%. Segment gross margins were 87.4% for Surgical Glaucoma and 29.1% for Dry Eye, compared with 86.1% and 13.1%, respectively, in FY2021. Management attributed margin improvement mainly to higher OMNI volume and manufacturing efficiencies; Dry Eye cost of goods sold included $0.9 million related to the SmartHub 1.0 recall.
At year-end, cash and cash equivalents were $185.0 million, down from $260.7 million; current assets were $209.7 million and current liabilities $17.8 million. The company reported $35.0 million principal outstanding under its term loan ($33.3 million net carrying amount) and an undrawn $5.0 million revolver. The debt is secured by substantially all assets, including material intellectual property; the stated term-loan rate is reserve-adjusted SOFR plus 7.00%. Principal payments were scheduled to begin in December 2023, with a potential extension to December 2024 subject to conditions. The company reported compliance with covenants at year-end.
Management stated that cash, cash equivalents and available credit were expected to fund planned operations for at least the next 12 months. The filing cautions that this outlook depends on assumptions and that additional financing may be needed. The company has incurred losses since inception and expects further losses. FY2022 research and development expense was $22.9 million; selling, general and administrative expense was $120.1 million.
Material changes and developments
- Revenue grew 45.7%, primarily from increased OMNI units and utilization, broader facility ordering, the SION launch, and growth in TearCare’s installed base.
- Operating expenses grew faster than revenue, and net loss increased by $23.3 million. Higher staffing and stock-based compensation contributed to increased R&D and SG&A spending.
- Operating cash use increased to $76.0 million. FY2021 financing cash flow included $252.2 million of net IPO proceeds; FY2022 financing cash flow was $1.2 million.
- Management reported a voluntary recall of legacy SmartHub 1.0 TearCare systems after FDA communications about the system’s 510(k)-exempt status. The recall did not involve the newer cleared system; the company reported completing recall activities and requesting closure in Q4 2022.
- The CFO stepped down effective January 2023; the company named its Vice President of Finance and Corporate Controller interim CFO.
Outlook, risks and contingencies
- Commercial and reimbursement risks: Results depend heavily on OMNI, and SION was newly launched. TearCare lacks formal Medicare and private-payer coverage, and patients typically pay out of pocket. Changes to coverage, reimbursement, or CPT code 66174 could affect adoption and revenue; management disclosed Medicare physician payment reductions for code 66174 through 2023.
- Clinical and regulatory risks: The company is pursuing further clinical evidence and expanded indications, including the PRECISION IDE study for canaloplasty alone and the SAHARA TearCare study. Long-term safety and effectiveness data remain limited. EU regulatory transition and certification requirements could affect international sales.
- Manufacturing and supply: The company depends on third-party manufacturers and limited or single-source suppliers. OMNI production is primarily with a manufacturer in China, although a U.S.-based manufacturer is also contracted. Supply interruptions, quality issues, or geopolitical tensions could constrain sales.
- Competition and execution: Larger, better-resourced competitors, slow clinician adoption, the need for market education, and the company’s substantial ongoing losses could impede growth or profitability.
- Debt and funding: The company may require additional capital; financing may be unavailable or dilutive, and debt covenants and collateral could constrain operations.
- Legal matter: Sight Sciences’ patent infringement suit against Ivantis and Alcon over the Hydrus Microstent was pending. Defendants challenged the patents, including through inter partes review petitions. A jury trial was scheduled for April 2024. The company said it could not predict the outcome or reasonably estimate the financial impact.
- Controls: Management concluded disclosure controls and internal control over financial reporting were not effective at year-end because of a material weakness involving insufficient accounting resources and technical expertise. Remediation was ongoing and required further validation and testing. The auditor did not attest to internal control effectiveness.
- Other: COVID-19-related disruptions, elective-procedure demand, product liability, intellectual property protection, privacy and cybersecurity, and healthcare regulatory compliance remain identified risks. The company provided no specific revenue or earnings guidance in the supplied filing text.
Key facts investors should verify
- Whether OMNI growth, SION adoption and TearCare expansion continue, and whether revenue concentration in OMNI declines.
- Whether TearCare obtains broader reimbursement and whether clinical studies support adoption and expanded indications.
- Cash burn, liquidity runway, availability of the revolver, term-loan extension conditions, and compliance with debt covenants.
- Progress in remediating the material weakness and the effectiveness of controls over subsequent reporting periods.
- Outcome and potential financial consequences of the patent litigation and related patent-review proceedings.
- Recall closure status and any further FDA actions, as well as continuity and quality of manufacturing supply.